Something More

Rules 10b-5(a) and (c) establish securities fraud liability for deceptive devices, schemes, and acts. One issue courts have considered is whether “scheme liability” requires a defendant to have engaged in fraudulent conduct beyond the making of material misrepresentations or omissions (which is specifically prohibited by Rule 10b-5(b)).

In Public Pension Group v. KV Pharmaceutical Co., 2012 WL 1970226 (8th Cir. June 4, 2012), the court found that the only non-conclusory “scheme liability” allegations were based on the defendants’ supposed knowledge of misstatements concerning the company’s FDA compliance and earnings. The court held that these allegations were deficient, “join[ing] the Second and Ninth Circuits in recognizing a scheme liability claim must be based on conduct beyond misrepresentations or omissions actionable under Rule 10b-5(b).”

Holding: Dismissal affirmed in part and reversed in part.

Leave a comment

Filed under Appellate Monitor

Supreme Court To Address Fraud-On-The-Market Theory

A key development this week was the Supreme Court’s decision to hear the Amgen Inc. v. Connecticut Retirement Plans and Trust Funds case on appeal from the Ninth Circuit. Pursuant to the fraud-on-the-market theory, reliance by investors on a misstatement is presumed if the company’s shares were traded on an efficient market that would have incorporated the information into the stock price. The fraud-on-the-market presumption is routinely invoked in securities class actions to justify the grant of class certification because it removes the potential need for individual evaluations of reliance.

At issue in the Amgen case is a circuit split over whether a plaintiff must prove that the misstatement was material to invoke the fraud-on-the-market theory in support of class certification. Three circuit courts (Second, Fifth and, to a lesser extent, the Third) previously have held that this is a required part of the fraud-on-the-market analysis when evaluating whether a class should be certified. The Ninth Circuit joined a decision from the Seventh Circuit, however, in rejecting that position. The court held that materiality is a merits question that does not affect whether class certification is appropriate.

The Amgen case picks up threads from two other recent Supreme Court decisions. In Matrixx, the Court addressed the issue of materiality, but only in the context of what must be plead to survive a motion to dismiss. Meanwhile, in Halliburton, the Court found that a plaintiff does not have to prove loss causation to invoke the fraud-on-the-market presumption, but left open the question of whether the plaintiff must demonstrate that the misstatement had a stock “price impact” (which is often used as a proxy for determining whether the misstatement was material). As a practical matter, if the Court were to find that lower courts should be evaluating whether the misstatement was material in determining whether to grant class certification, it obviously would reinvigorate class certification as a meaningful hurdle in prosecuting securities class actions.

Scotusblog has all of the relevant links, including to the amicus briefs filed in conjunction with the cert petition. The case will be heard next term.

Leave a comment

Filed under All The News That's Fit To Blog, Appellate Monitor

Bear Stearns Settles (Former Executives)

Former executives of Bear Stearns Cos. (now owned by J.P. Morgan Chase) have agreed to a preliminary settlement of the securities class action pending against them in the S.D.N.Y. The case, originally filed in 2008, accuses the executives of misleading investors about the firm’s business and financial well-being in the run-up to the credit crisis. The settlement comes after the denial of the defendants’ motion to dismiss, but before class certification.

The settlement is for $275 million, making it one of the top 40 largest securities class action settlements since 1995 (as stated in the court filing). According to the Wall Street Journal (subscrip. req’d), however, the executives will not have to make any personal payments. Instead, the settlement amount will come from a $9 billion fund created by J.P. Morgan Chase to cover Bear Stearns-related litigation and other expenses.

Leave a comment

Filed under Settlement

Appellate Roundup

The Second Circuit and Seventh Circuit have issued recent notable decisions.

(1) Item 303(a) of Regulation S-K requires issuers to disclose known trends or uncertainties “reasonably likely” to have a material effect on operations, capital, and liquidity. While it has been referred to as the “sleeping tiger” of securities litigation, it may soon be the star of the circus. In Panther Partners Inc. v. Ikanos Communications, Inc., 2012 WL 1889622 (2nd Cir. May 25, 2012), the Second Circuit added to its Item 303(a) jurisprudence, finding that the plaintiffs had plausibly alleged that the company, at the time of its securities offering, “was aware of the ‘uncertainty’ that it might have to accept returns of a substantial volume, if not all, of the chips it had delivered to its major customers.”

Holding: Denial of leave to file an amended complaint (based on futility) reversed.

(2) He’s back and so soon! Following up on last month’s decision, Judge Easterbrook of the Seventh Circuit has authored another securities litigation opinion. In Plumbers and Pipefitters Local Union 719 Pension Fund v. Zimmer Holdings, Inc., 2012 WL 1813700 (7th Cir. May 21, 2012) (Easterbrook, J.), the court addressed whether the plaintiffs had adequately plead scienter (i.e., fraudulent intent) in a case alleging that the company downplayed the significance of product problems. Among other things, the plaintiffs pointed to the CEO’s failure, in response to a question posed during an analyst call, to reveal that the company had received verbal notice from an FDA inspector of “significant objectionable conditions” at one of its plants. The court concluded that the CEO’s answer was technically accurate and the “worst one could say about [the] answer is that it was evasive, which is short of fraudulent.”

Holding: Dismissal affirmed.

Leave a comment

Filed under Appellate Monitor

Back From The Dead

Can a plaintiff in a securities class action use information gained through the discovery process to resurrect previously dismissed claims? In In re Constellation Energy Group, Inc. Sec. Litig., 2012 WL 1067651 (D. Md. March 28, 2012), the court dismissed all of the fraud claims (1934 Act), but allowed the non-fraud claims (1933 Act) to proceed. Following discovery, the plaintiff argued that it had found “new evidence of scienter” and moved for lead to amend its complaint to re-plead the fraud claims.

The court held that neither the plain language nor the purpose of the PSLRA would be frustrated by allowing the fraud claims to go forward. The PSLRA’s discovery stay provision (which stays all discovery pending the resolution of a motion to dismiss) was designed to “limit the pressure on innocent defendants to settle cases in lieu of proceeding to expensive discovery” not “to shield all defendants from any adverse evidence that may properly be discovered over the course of litigation.” Moreover, the case was still ongoing against the same defendants, so they would not be prejudiced by having to defend themselves against the new claims. In this instance, however, the court denied the motion for leave to amend as futile, finding that even with the new evidence the plaintiff had failed to satisfy the “strong inference” pleading standard for scienter.

Holding: Motion for leave to amend denied.

Leave a comment

Filed under Motion To Dismiss Monitor

Balancing Act

There is rarely a dull moment when Judge Frank Easterbrook writes a securities litigation opinion. In Fulton County Employees Retirement System v. MGIC Investment Corp., 675 F.3d 1047 (7th Cir. April 12, 2012) (Easterbrook, J.) the court addressed a credit crisis case in which a mortgage loan insurer allegedly made misstatements about the liquidity of an affiliated company. The decision includes a few interesting holdings.

(1) MGIC stated in a press release that the affiliated company (in which MGIC held a 46% interest) had “substantial liquidity,” but eleven days later announced that its investment in the affiliated company was “materially impaired.” The court concluded that the liquidity statement was inactionable both because it was true when made and because the press release contained specific warnings about the liquidity risk at the affiliated company.

(2) Moreover, the court noted that the events that led to the material impairment of the investment were known to the market. To the extent that the “whole world knew that firms that had issued, packaged, or insured subprime loans were in distress,” MGIC was in no better position to foresee what would happen to its investment than anyone else.

(3) The plaintiffs also alleged that certain statements made by officers of the affiliated company during MGIC’s earnings call were fraudulent. The court held that (a) MGIC’s ownership interest in the affiliated company was insufficient to establish that it “controlled” the affiliate (especially given that another company also had a 46% stake) for purposes of control person liability, and (b) pursuant to the recent Janus decision, MGIC could not be held liable as a “maker” of the affiliated company’s statements and had no duty to correct them.

Holding: Dismissal affirmed.

Quote of Note: “The press release went on to detail problems that MGIC was encountering, including the liquidity risk at [the affiliated company]. The goal of this paragraph was to let investors know about the trouble without painting too gloomy a picture. A balancing act of that nature cannot sensibly be described as fraud.”

Leave a comment

Filed under Appellate Monitor

Public Red Flags

The efficient market hypothesis can be a double-edged sword for plaintiffs. While it is necessary to support a presumption of reliance in securities class actions, it also makes courts skeptical of any theory of fraud that is based on the corporate defendant failing to inform the market about the impact of known events.

In City of Omaha, Nebraska Civilian Employees’ Retirement System v. CBS Corp., 2012 WL 1624022 (2d Cir. May 10, 2012), the plaintiffs alleged that CBS should have performed an impairment test on its goodwill and disclosed the results several months before it actually did so in October 2008. The Second Circuit affirmed the dismissal of the case on two grounds.

First, the court held, based on on its prior Fait decision, that estimates of goodwill are statements of opinion. The plaintiffs’ failure to allege “that defendants did not believe in their statements of opinion regarding CBS’s goodwill at the time they made them” was fatal to their securities fraud claims.

Second, the court found that “all of the information alleged to constitute ‘red flags’ calling for interim impairment testing . . . were matters of public knowledge.” Given the efficiency of the market for CBS stock, the price therefore “would at all pertinent times have reflected the need for, if any, or culpable failure to undertake, if any, interim impairment testing.” Under these circumstances, the complaint did not allege in a plausible fashion that “the market price of CBS stock was inflated by a fraud” and that the plaintiffs relied upon that fraudulently inflated price.

Holding: Dismissal affirmed.

Leave a comment

Filed under Appellate Monitor

Mr. Roberts Heads Across Town

On a personal note, Lyle Roberts (the author of The 10b-5 Daily) has joined the Washington, DC office of Cooley LLP. The firm’s press release can be found here. Posting has been correspondingly light, but will pick up shortly.

Leave a comment

Filed under All The News That's Fit To Blog

Medtronic Settles

Medtronic, Inc. (NYSE: MDT), a Minneapolis-based medical technology company, has announced the preliminary settlement of the securities class action pending against the company in the D. of Minnesota. The case, originally filed in 2008, stems from allegations that the company and certain of its officers made materially false statements regarding the extent to which revenue from one of its products, the Infuse bone graft, depended on applications not approved by the FDA (i.e., “off-label” uses).

The settlement is for $85 million. Reuters has an article. The 10b-5 Daily previously has posted about the court’s decision to certify the proposed class over the defendants’ objection that the plaintiffs could not adequately represent the class “because of alleged misrepresentations counsel made in the Amended Complaint regarding the testimony of the confidential witnesses.”

Leave a comment

Filed under Settlement

A CLE Program You Will Definitely Want To Attend

With that bold claim, do you have some availability on Thursday, April 26 to participate in a continuing legal education (CLE) program in New York or view a live webcast? It is not too late to sign up for PLI’s Handling a Securities Case: From Investigation to Trial and Everything in Between.

Lyle Roberts of Dewey & LeBoeuf (the author of The 10b-5 Daily) is co-chairing the program. The outstanding faculty will cover a wide range of topics, all while following a hypothetical case from the initial investigation through trial. There will even be a panel on ethical issues, for those in need of ethics credits.
Hope to see you there.

Leave a comment

Filed under All The News That's Fit To Blog